We are off to a strong start in 2026, building on the momentum generated over the past year while entering into a transformational agreement designed to position Cumberland for its next phase of growth.
We recently announced a Strategic Transaction with Apotex Inc. to integrate our branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire Cumberland’s portfolio of FDA-approved brands for $100 million in cash consideration, subject to shareholder approval. The transaction is designed to unlock value and sharpen our focus on advancing our pipeline of differentiated product candidates designed to address unmet medical needs.
We also continued to make meaningful progress across our clinical pipeline. In February, the FDA granted Fast Track Designation to our ifetroban candidate for the treatment of heart disease in patients with Duchenne muscular dystrophy (DMD).
During the first quarter, we shared several important developments across our product portfolio, including:
- Initiation of the national promotional campaign for Talicia®, our newest portfolio addition designed to treat the serious stomach infections associated with H. pylori bacteria.
- Receipt of FDA approval for an expanded indication for Caldolor® to include the management of postoperative pain, supporting the shift toward non-opioid and opioid-sparing pain management approaches.
- Launch of the new Sancuso® website to provide healthcare professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced side effects.
We also announced first-quarter financial results. Our portfolio of FDA-approved brands generated combined revenues of $9.1 million during the quarter, representing a 5% increase after excluding a prior-year one time milestone payment.
We are entering an exciting period for Cumberland. The planned integration of our commercial business with Apotex, along with continued advancement of our pipeline, is expected to position the Company for long-term growth and value creation.
We look forward to sharing additional updates and accomplishments as the year progresses.